As the Vice President of Clinical Affairs, Dr. Eric Sredzinski is responsible for the Clinical Management, Disease State Management, training, and implementation of patient adherence and persistence programs for Avella Specialty Pharmacy. Working closely with the company’s Oncology, Infectious Disease, and Transplant teams for presentations and business development, Dr. Sredzinski, a member of Avella Specialty Pharmacy’s top management since joining the company in 2001, is also responsible for the management of manufacturer contracted data sets, including the participation in the development and testing of the data layout.
Graduating with a Doctor of Pharmacy degree from the University of Arizona College of Pharmacy (2000), Dr. Sredzinski focused his training in oncology/infectious disease. Following a pharmacy internship at Tucson Medical Center, he completed his pharmacy practice residency at the Southern Arizona VA Medical Center in Tucson, where he worked with the oncology team and the prostate and neurologic cancer department. Dr. Sredzinski worked as the clinical pharmacist for Arizona Oncology’s autologous PSCT team where he assisted in the medication management of all pre and post-transplant patients.
Dr. Sredzinski is an active member of ASHP, The Arizona Pharmacists Association, HOPA, ASCO, and the AAHIVP. Dr. Sredzinski is currently involved in an NIH trial evaluating adherence and persistence in renal transplant patients that was recently presented at the American Transplant Congress and has been accepted for publication. Additional research in ADHD, the management of anticoagulated patients and trends in antidepressants, has been presented. Dr. Sredzinski currently presents to local, regional, and National organizations on a number of health topics, including adherence and persistence. Dr. Sredzinski is also active in community education, and has frequently presented to the HIV and Organ Transplant groups.